Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Drop in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 15,200 shares, a decline of 14.1% from the June 30th total of 17,700 shares. Approximately 1.2% of the company’s shares are short sold. Based on an average daily trading volume, of 7,200 shares, the short-interest ratio is presently 2.1 days.

Creative Medical Technology Trading Down 2.5 %

Shares of NASDAQ CELZ traded down $0.09 during trading hours on Tuesday, reaching $3.47. The stock had a trading volume of 3,448 shares, compared to its average volume of 93,671. The firm has a market cap of $4.68 million, a price-to-earnings ratio of -0.93 and a beta of 2.12. The business’s fifty day moving average price is $3.88 and its two-hundred day moving average price is $4.43. Creative Medical Technology has a 52-week low of $2.90 and a 52-week high of $10.28.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, May 10th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.42. Equities research analysts anticipate that Creative Medical Technology will post -3.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC lifted its position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,570 shares of the company’s stock after acquiring an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned 1.45% of Creative Medical Technology worth $75,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.